Despite these setbacks, the unique mechanism of action of DUB inhibitors in Bortezomib-resistant multiple myeloma has prompted further research, including the development of a rat model to assess VLX1570-induced lung toxicity and the development of specific DUB inhibitors [199]. Here, ZUP1 is linked to plasma cell myeloma.